Studies On uro'gen III synthase with modified bilanes

Bioorganic & Medicinal Chemistry Letters
1994.0

Abstract

Four new hydroxymethylbilane analogs have been prepared and their activities as substrates/inhibitors of Uroporphyrinogen III synthase investigated.Uroporphyrinogen III (Uro'gen Ill) synthase (EC 4.2.1.75) is the enzyme in the porphyrinoid pathway which cyclizes the linear tetrapyrrole hydroxymethylbilane (HMB, 1) to Uro'gen III (2) with intramolecular rearrangement of the ring D. In the absence of the enzyme, HMB ringcloses chemically without ring inversion to form Uro'gen I (3, scheme 1). Since Uro'gen III is a key precursor of many vital pigments present in living system (heme, chlorophyll, coenzyme F 430, vitamin B12), numerous studies on the substrate specificity and the mechanism of Uro'gen III synthase have been performed.1As a part of our continuing effort to unravel the mechanism of this fascinating enzyme, several modified bilanes (4 to 7)[three substituted by a methyl group at the C-20 (HEB, 4) N-24 (ND-Me-HMB, 5) and N-23 (Nc-Me-HMB, 6) positions and the fourth by elongation of the ring D propionate side-chain to a butyrate (butyrate-HMB, 7)(table l)] have been synthesized.2 Their ability to function as substrates or inhibitors have then been determined with the goal of gaining indirect information about the active site and eventually of leading to the preparation of novel Uro'gen III analogs, otherwise difficult to obtain.A=CH2CO2H; P=CH2CH2CO2HScheme 1| | $R_1$ | $R2$ | R3 | R4 | $R5$ | $R_6$ | R 7 | $R_8$ | R9 | $R_{10}$ | $R_{11}$ | $R_{12}$ | | s | ref ||----|-------|------|----|----|------|-------|----------------|-------|----|----------|----------|----------|---|----------|-----|| | Α | Ρ | Α | P | Α | P | Α | P | н | н | н | н | | $f{+}$ | 8 || 4 | Α | P | Α | Ρ | Α | P | Α | P | н | н | н | Me | ┿ | | || 5 | Α | P | А | P | А | P | Α | P | н | Me | Н | н | | | || 6 | А | Р | А | P | А | P | Α | P | н | н | Me | н | ÷ | | || 7 | Α | P | Α | Р | Α | P | Α | В | н | н | Н | Н | | | || 89 | P | Α | Α | P | Α | P | Α | P | н | н | н | н | | | || 9 | А | P | P | Α | A | P | Α | P | н | н | н | Н | | | || -0 | Α | P | Α | P | P | Α | Α | P | н | н | н | н | | | || | А | P | Α | P | Α | P | P | Α | н | н | Н | н | | | || 2 | P | Α | P | А | P | Α | Α | P | н | н | н | н | | | || 3 | А | P | Α | P | Α | P | Me | P | н | н | н | н | | $^{(+)}$ | 5 || 4 | А | P | Α | P | Α | P | A | Et | н | н | н | н | | ┿ | 5 || 5 | А | P | А | P | Α | P | Α | P | Me | н | Н | Н | | | 6 || 6 | A | P | Α | P | Α | P | Α | P | αv | н | Н | н | | | 6 || | Α | P | Α | P | Α | P | A | Р | Br | н | н | н | | | |$A=CH_2CO_2H$ ; P=CH2CH2CO2H; B=CH2CH2CH2CO2HI=inhibitor; S=substrate; +=yes; -=no; (+)=poor substrateTable 1Similar studies have been conducted elsewhere with other HMB analogs, such as bilanes with different acetate and propionate side-chain arrangements (8,s 9-l 24), 17-methylbilane (13),5 18-ethylbilane (14)s and 1 g-substituted HMB [19-methyl-HMB (15) and 19-cyano-HMB (1 S)]s. Recently, our group synthesized the 19-bromo-HMB (17) and studied its reactivity with Uro'gen III synthase. 7 Table 1 summerizes these results together with those obtained with our new synthetic analogs.The Uroporphyrin (Uro) content of incubations of bilanes 4 to 7 with Uro'gen III synthase were analyzed by HPLC-UV to determine the ratio of type l/type Ill10 following the usual assay procedure.11 Uro III analog production was observed only with the butyrate-HMB 7. Kinetic data using a Lineweaver-Burk plot gave a Km of 20 pM for this substrate versus 3 pM for HMB. Analog 7 appeared to be turned over at about half the rate of the natural substrate, HMB.Inhibition studies were carried out with the three other new bilanes (4, 5 and 8) all of which exhibited a decrease of enzyme activity consistent with a reversible inhibition with respect to HMB. This effect was overcorned by increasing the substrate concentration, showing the inhibition to be competitive. The kinetic parameters (Ki) were not formally determined, since no extra information concerning the active site or the enzymatic mechanism would be gained. However, HPLC analysis showed clearly that ND-Me-HMB (5) is a better inhibitor than NC-Me-HMB (8) or HEB (4) (less Uro'gen III formation observed).The activity of Uro'gen III synthase with the butyrate-HMB (7) and with ND-Me-HMB (5) was also investigated by tsC-NMR. Both bilanes were synthesized with a tsC-label at the C-20 position.12 The incubations were run in an NMR tube using conditions described earlier's (millimolar concentration, 5"C, in 20% methanol or 10% acetonitrile/sodium bicarbonate buffer, pH 10 to 10.8). As expected, the butyrate bilane (7, 6=55.5 ppm for C-20) was observed to turn over slowly at pH 10 generating the corresponding Uro'gen type product (6=22 ppm), confirmed as type III by HPLC analysis of the sample.10 No new peak consistent with an intermediate was seen. With ND-Me-HMB (5, 6=55.4 ppm for C-20), no change in the NMR spectrum [no Uro'gen (6~22.0 ppm) or Uro product (&9&O ppm)] was perceived during overnight incubation.Recently, we have been able to provide evidence of the generation of an azafulvene at C-l as the first step of the Uro'gen III synthase mechanism by trapping this species with ammonium chloride to form the laminomethylbiiane.t3 An experiment with analog 5 under similar conditions (200 mM ammonium chloride) showed no signal at ca. 36 ppm expected for the aminomethylbilane, indicating that the ND-Me-HMB is unable to form an azafulvene at C-l. It can be speculated that the presence of the N-methyl group does not allow the correct conformation of the bilane inside the active site pocket.A survey of all the results to date of substrate/inhibition studies with HMB analogs (table 1) indicates that only bilanes bearing modified sidechains (7, 10, 11, i 3 and 14) can be alternate substrates, while other substituted HMB's (4 to 6 and 15 to 17) act as inhibitors, showing that Uro'gen Ill synthase is not an absolutely specific enzyme. Nevertheless, HMB remains the best substrate, as these side-chain modifications produced a substantial adverse effect on the reaction rate and/or efficiency of the inversion process (ratio of ring D inversion: 80% for 7, 95% for 10, 45% for 11 and 65% for 14).In contrast to other side-chain permutations, inversion of the propionate and acetate groups on ring A (8 and 12) and on ring B (9) bring about more drastic changes, as the bilanes 8, 9 and 12 are not substrates of the enzyme. Any change in the side-chains creates some electronic effect in the pyrrolic ring and particularly concerning ring A, a variation of the pK of the hydroxy group could be expected. In the light of recent evidence involving the generation of an azafulvene at C-l, i.e. at ring A, as the first step of the enzymatic mechanism, 13 it is likely that the inversion of the side-chains on ring A would affect the formation of the azafulvene. The result for ring B is more difficult to interpret.As for the ring 0, substitution of the acetate group by a methyl (13) yields a very poor substrate, indicating that the ring D acetate carboxylgroup must have an important function, whereas the ring D propionate carboxyl group apparently plays a less critical role (7 and 14).Uro'gen Ill synthase appears not to tolerate any other changes than sidechain modifications. Indeed, inhibition is brought about by substitution at the C-19 position (15 to 17), methylation of the ring C and D pyrrolic nitrogen (5 and 6) and by substitution at the hydroxymethyl side-chain (4). The first effect is easily understood, as the substitution will directly influence the cyclization process. A disto~ion in the conformation of the enzyme-bound bilane engendered by the presence of the methyl group on the pyrrolic nitrogen might explain the second case. The inhibition by 4 could equally be explained on the basis of steric hindrance, which may not allow the enzymatic formation of the azafulvene at C-l.In summary, the activities as substrates/inhibitors of Uro'gen III synthase of four new bilanes have been studied. Of these, one (butyrate-HMB) is acting as a slow substrate to give a Uro'gen type Ill product while the three others (HEB, NC-~e-H~B and ND-~e-H~B) show competitive inhibition. A comparison of substrate specifitylinhibition effect of diverse bilanes with Uro'gen III synthase in view of all the structureactivity results to date suggests that the synthase can tolerate sidechain modifications to some degree, however other changes usually result in inhibition of the enzyme. No conclusive information about the enzyme mechanism could be obtained, warranting further studies to probe this unique mechanism.

Knowledge Graph

Similar Paper

Studies On uro'gen III synthase with modified bilanes
Bioorganic & Medicinal Chemistry Letters 1994.0
Normal and abnormal heme biosynthesis. Part 7. Synthesis and metabolism of coproporphyrinogen-III analogues with acetate or butyrate side chains on rings C and D. Development of a modified model for the active site of coproporphyrinogen oxidase
Bioorganic & Medicinal Chemistry 2011.0
Mechanism-based inactivation of porphobilinogen synthase: Substitution of ketone functionality in the substrate with a thioester
Bioorganic & Medicinal Chemistry Letters 1995.0
Biosynthesis of Corrinoids and Porphyrinoids. IX. Studies on the Origin of Oxygen of Uroporphyrinogen III in Arthrobacter hyalinus.
Chemical and Pharmaceutical Bulletin 1994.0
Enzymic synthesis and structure of precorrin-3, a trimethyldipyrrocorphin intermediate in vitamin B12 biosynthesis
Biochemistry 1992.0
Purification, <i>N</i>-terminal amino acid sequence and properties of hydroxymethylbilane synthase (porphobilinogen deaminase) from <i>Escherichia coli</i>
Biochemical Journal 1986.0
Synthesis and enzyme inhibitory activities of some new pyrazole-based heterocyclic compounds
Medicinal Chemistry Research 2012.0
Bisindolylmethane thiosemicarbazides as potential inhibitors of urease: Synthesis and molecular modeling studies
Bioorganic &amp; Medicinal Chemistry 2018.0
The synthesis, structure and activity evaluation of pyrogallol and catechol derivatives as Helicobacter pylori urease inhibitors
European Journal of Medicinal Chemistry 2010.0
Biosynthesis of porphyrins and related macrocycles. Part 20. Purification of deaminase and studies on its mode of action
Journal of the Chemical Society, Perkin Transactions 1 1983.0